After investing heavily in both mechanisms for IO-IO combinations, Merck is cutting its losses with vibostolimab and favezelimab, and switching its anticancer bets to other modalities.
Once a key part of its next-generation plans in cancer, Merck & Co. has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
